NCT00911794

Written Disclosure Therapy for Anxiety and Stress in Patients With Chronic Lung Disease

Pulmonary Therapy and Supplemental Written Disclosure Therapy for Chronic Lung Disease

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 66 (actual)
• Sponsor: Winthrop University Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether Written Disclosure Therapy (WDT) is of any benefit to patients with chronic lung diseases who are participating in pulmonary rehabilitation.

Detailed description

Chronic lung diseases are typically associated with impaired quality of life, stress, and anxiety. Written disclosure therapy (WDT) reduces stress in patients with a variety of chronic illnesses. We sought to determine if written disclosure therapy benefits patients with chronic lung diseases when it is added as a component to the pulmonary rehabilitation program.

Conditions

• Chronic Lung Diseases
• COPD
• Pulmonary Fibrosis

Interventions

Type	Name	Description
OTHER	Disclosure Writing (Written Disclosure Therapy)	Patients write about a stressful life experience
OTHER	Neutral (Sham) Writing	Patients write about neutral subjects

Timeline

• Start date: 2007-01-01
• Primary completion: 2008-01-01
• Completion: 2009-03-01
• First posted: 2009-06-02
• Last updated: 2009-06-02